Company Profiles

driven by the PitchBook Platform

Akinion Pharmaceuticals

Description

Operator of a drug development company focusing on the treatment of acute myeloid leukemia (AML). The company develops kinase receptor inhibitors for the treatment of acute myeloid leukemia.

2009

Founded

PRIVATE

Status

11-50

Employees

Early Stage VC

Latest Deal Type

3

Investors

Description

Operator of a drug development company focusing on the treatment of acute myeloid leukemia (AML). The company develops kinase receptor inhibitors for the treatment of acute myeloid leukemia.

Website:

www.akinion.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals

Primary Office

Karolinska Institutet Science Park Nobels väg 3 171 65 SolnaSweden +46 (0)8 524 869 65
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Akinion Pharmaceuticals's full profile, request a free trial.

    Akinion Pharmaceuticals Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Akinion Pharmaceuticals Investors (3)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    btov PartnersVenture CapitalMinority000 0000000 0000
    Karolinska DevelopmentVenture CapitalMinority000 0000000 0000
    Rosetta Capital(London)Venture CapitalMinority000 0000000 0000
    btov Partners Venture Capital
    Karolinska Development Venture Capital
    Rosetta Capital(London) Venture Capital

    Akinion Pharmaceuticals Executive Team (8)

    NameTitleBoard
    Seat
    Contact
    Info
    Lars Abrahmsén Ph.DVice President of Preclinical Development & Chief Scientific Officer
    Kristina CarlssonDirector, Regulatory Affairs
    Mikael von Euler Ph.DChief Medical Officer & Vice President, Clinical Development
    Birgitta StåhlVice President & Chief Operating Officer
    John MeewellaChief Executive Officer
    Lars Abrahmsén Ph.D Vice President of Preclinical Development & Chief Scientific Officer
    Kristina Carlsson Director, Regulatory Affairs
    Mikael von Euler Ph.D Chief Medical Officer & Vice President, Clinical Development
    Birgitta Ståhl Vice President & Chief Operating Officer
    John Meewella Chief Executive Officer

    Akinion Pharmaceuticals Board Members (4)

    NameRepresentingRoleSinceContact
    Info
    Graham Fagg Ph.DRosetta Capital(London)Partner000 0000
    Michael MooreAkinion PharmaceuticalsChairman000 0000
    Stefan Fraenkel Ph.DSelfBoard Member000 0000
    Viktor DrvotaAkinion PharmaceuticalsBoard Member000 0000
    Graham Fagg Ph.D Partner Rosetta Capital(London)
    Michael Moore Chairman Akinion Pharmaceuticals
    Stefan Fraenkel Ph.D Board Member Self
    Viktor Drvota Board Member Akinion Pharmaceuticals
    Request full access to PitchBook